How to Determine Whether a Protein Is Suitable for Targeted Degradation: From Degradation Pathway and Molecular Design to Mechanism Validation

The core question in targeted protein degradation is: “Can the cell be made to remove this protein, and can the removal process be proven to follow the expected mechanism?” Cellular protein levels are jointly regulated by synthesis, folding, localization, and degradation. The two systems most closely related to targeted degradation are the ubiquitin–proteasome system (UPS) and the lysosomal proteolytic pathway. The ubiquitin–proteasome system mainly processes intracellular proteins that have been tagged with ubiquitin; the lysosomal pathway can process target proteins, protein complexes, or protein aggregates that enter lysosomes through endocytosis, autophagy, or related processes.

1. Does This Protein Really Need to Be Degraded?

The first question in targeted protein degradation is whether the research goal truly requires lowering the level of the target protein itself, rather than simply blocking one of its active sites.

If the pathogenic or abnormal function of a protein mainly comes from enzymatic activity, receptor activity, or a clearly defined binding site, and existing inhibitors can stably control the downstream phenotype, an inhibition strategy is usually the more direct option. If the target protein still retains scaffold functions, protein–protein interaction functions, transcriptional regulatory functions, or complex assembly functions after inhibition, or if accumulation of the abnormal protein itself is the source of the problem, targeted degradation should be considered to reduce the protein level.

Question to assess	Situations suitable for considering targeted degradation	Situations where an inhibition strategy may already be sufficient
Where does the abnormal function come from?	Protein overexpression, abnormal stability, abnormal accumulation, mislocalization, or abnormal interactions	Mainly from a clearly defined enzymatic active site or receptor active site
Can an inhibitor solve the core phenotype?	After activity inhibition, the protein still participates in complex assembly, signaling scaffold functions, or transcriptional regulation	The inhibitor can stably block the key pathway and cellular phenotype
Is it necessary to remove the protein itself?	The research question requires an effect close to “protein knockdown” or “protein clearance”	Only short-term and reversible blockade of a specific function is needed
Does the target have non-enzymatic functions?	The protein has structural scaffold, protein interaction, or regulatory complex functions	The protein function mainly depends on a single catalytic activity
Does reducing the protein have verifiable significance?	There are clear downstream signaling, cellular phenotype, or disease-related readouts after protein reduction	The functional consequence of protein reduction is unclear, making experimental conclusions difficult to interpret

Targeted protein degradation is a research strategy for solving specific problems. It is suitable for answering the following questions: whether cellular function changes after the protein is removed; whether this change differs from simple inhibition; and whether the target protein exerts its function through its physical presence rather than through a single active site.

2. Select the Degradation Pathway Based on Protein Location and Accessible Regions

The location and accessible regions of the target protein determine which pathway should be prioritized. If the pathway is misjudged, molecular design may deviate from the correct direction from the very beginning.

Target protein location or state	Preferred degradation route	Suitable technical direction	Key points to assess
Cytosolic protein	Ubiquitin–proteasome system	Proteolysis-targeting chimera (PROTAC)	Whether the molecule can enter the cell and simultaneously access the target protein and the E3 ubiquitin ligase
Nuclear protein	Ubiquitin–proteasome system	Proteolysis-targeting chimera	Whether the degrader can form an effective complex in the relevant nuclear environment
Intracellular domain of a membrane protein	The ubiquitin–proteasome system, the endocytosis–lysosome pathway, or other quality-control routes should be specifically evaluated	Proteolysis-targeting chimera or other intracellular degradation strategies	Whether the ligand can access the intracellular domain; whether protein reduction is affected by proteasome or lysosome inhibition experiments
Extracellular domain of a membrane protein	Lysosomal pathway	Lysosome-targeting chimera (LYTAC)	Whether the target protein can be internalized and delivered to lysosomes
Secreted protein or extracellular protein	Lysosomal pathway	Lysosome-targeting chimera or antibody-related degradation strategy	Whether there are modules that can bind both the target protein and the delivery receptor
Aggregated protein, damaged organelle, or large protein complex difficult for the proteasome to process	Autophagy–lysosome pathway	Autophagy-related targeted degradation strategy	Whether the cargo can enter autophagosomes or the lysosomal delivery process

The basic process of the ubiquitin–proteasome system is as follows: the target protein is tagged with ubiquitin through a cascade involving E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin ligases, and is then recognized and degraded by the proteasome. The lysosomal pathway relies on endocytosis, pinocytosis, phagocytosis, autophagy, or related processes to deliver protein complexes into the acidic hydrolytic environment inside lysosomes.

3. Does the Target Protein Meet the Requirements for Degrader Development?

Targeted degradation is not determined only by whether the target is important. It also depends on whether the target has practical conditions that can be acted upon.

Assessment item	What needs to be confirmed	Impact on the experiment
Whether a reliable ligand is available	Whether there is an existing small molecule, peptide, antibody, or other binding module	Without a binding module, degrader design is difficult to initiate
Whether the ligand can retain binding ability	Whether it still binds the target after attachment of a linker or conjugation module	An incorrect attachment site can directly lead to loss of activity
Whether the target is in an appropriate cellular compartment	Whether the target protein has an opportunity to contact the degradation system	Mismatched localization may lead to good binding in vitro but no degradation in cells
Whether the target protein meets the spatial requirements for degrader development	Whether a spatial relationship favorable for ubiquitination or endocytic delivery can be formed	Binding does not necessarily mean degradation
Whether the protein turnover rate is clear	Whether half-life, synthesis rate, and basal degradation level can be evaluated	Turnover that is too fast or too slow can affect result interpretation
Whether the detection method is reliable	Whether antibodies, mass spectrometry, fluorescence, or reporter systems are stable	An unstable detection system can cause false positives or false negatives
Whether functional readouts are available	Whether downstream signaling or cellular phenotypes can be detected after degradation	Protein reduction alone is still insufficient for mechanistic interpretation

A target suitable for further development should meet at least five basic conditions:

1. There is an available or developable target-protein binding module.

2. The target protein is clearly expressed in the target cells.

3. Reducing the protein level has clear research significance.

4. There is a reliable method to detect protein reduction.

5. There are verifiable downstream functional outcomes.

4. Feasibility of Degrader Design Through the Ubiquitin–Proteasome Pathway

A proteolysis-targeting chimera is a type of bifunctional molecule that usually consists of three parts: a target-protein ligand, an E3 ubiquitin ligase ligand, and a linker. Its role is not simply to occupy the target. Instead, it simultaneously binds the target protein and the E3 ligase, enabling ubiquitination of the target protein and subsequent degradation by the proteasome.

4.1 Is the Target-Protein Ligand Suitable for Conversion into a Degrader?

The target-protein ligand needs to answer four questions:

Question	Assessment points
Can it bind the target protein inside cells?	High in vitro affinity does not necessarily mean cellular effectiveness; cell permeability, intracellular concentration, and target localization also need to be considered
Is the attachment site appropriate?	The linker must not disrupt the key binding region
Must it be a strong inhibitor?	Not necessarily; a degrader requires stable binding and recruitment of the degradation system, which is not completely equivalent to inhibitory activity
Will it affect selectivity?	Both the selectivity of the original ligand and the selectivity after degradation need to be re-evaluated

Common reasons for target-protein ligand failure include:

1. The ligand shows a marked decrease in affinity after linker attachment.

2. The ligand binds purified protein but cannot effectively access the target protein inside cells.

3. The ligand-binding site does not favor bringing the target protein close to the E3 ligase.

4. The ligand binds multiple homologous proteins, resulting in a complex degradation profile.

4.2 Does the E3 Ligase Ligand Match the Target and Cell Model?

Common E3 ligase recruitment directions include cereblon (CRBN) and von Hippel–Lindau protein (VHL). When selecting an E3 ligase, the cell model and target protein must be considered together.

Assessment factor	What needs to be confirmed
Cellular expression	Whether the E3 ligase is sufficiently expressed in the target cells
Spatial contact	Whether the E3 ligase and target protein have an opportunity to exist in the same cellular region
Ternary complex	Whether the target protein, degrader, and E3 ligase can form a stable and effective complex
Off-target risk	Whether the E3 ligand may induce degradation of non-target proteins
Cellular tolerance	Whether long-term recruitment of this E3 ligase affects cellular protein homeostasis

4.3 Can the Linker Form an Effective Spatial Relationship?

A linker is not merely a “connecting line.” It is a structural module that determines the distance, orientation, flexibility, solubility, and cell permeability of the two ligands. Linker design directly affects ternary complex formation and degradation efficiency.

Linker factor	What it affects	Common problems
Length	Determines the spatial distance between the target protein and the E3 ligase	If too short, the proteins may be unable to approach each other; if too long, there may be too many conformations
Flexibility	Determines whether the molecule can adapt to the protein surface	Excessive flexibility may reduce the proportion of productive conformations
Rigidity	Helps fix orientation	Excessive rigidity may prevent adaptation to the protein surface
Hydrophilicity	Affects solubility and formulation stability	Insufficient hydrophilicity may lead to precipitation or adsorption
Hydrophobicity	Affects cellular entry and nonspecific binding	Excessive hydrophobicity may increase cytotoxicity
Attachment site	Determines whether both ligands retain effective binding	An incorrect attachment site may inactivate the target ligand or E3 ligand

Linker screening usually requires designing a series of molecules rather than synthesizing only one structure. A negative result may come from unsuitable linker length, attachment site, or conformation, and should not be taken as direct evidence that the target is unsuitable for degradation.

4.4 Can the Ternary Complex Convert “Binding” into “Degradation”?

A proteolysis-targeting chimera must accomplish three actions at the same time:

1. Bind the target protein.

2. Recruit the E3 ligase.

3. Bring the target protein close to the E3 ligase in an appropriate orientation so that ubiquitination can occur.

Therefore, even when two high-affinity ligands are connected, degradation may still not occur. What truly determines degradation efficiency is whether the ternary complex is stable, whether it shows cooperativity, whether ubiquitinatable regions of the target protein are exposed, and whether the complex configuration is favorable for ubiquitin transfer.

5. Feasibility of Targeted Delivery and Degradation Through the Lysosomal Pathway

Lysosome-targeting chimeras are mainly suitable for extracellular proteins, secreted proteins, and cell-surface proteins. They use one module that binds the target protein and another module that binds a cell-surface lysosomal delivery receptor, bringing the target protein into the endocytic pathway and then delivering it to lysosomes for degradation.

Assessment item	What needs to be confirmed	Consequence if not established
Whether the target protein is accessible from outside the cell	Whether the target is located extracellularly or on the extracellular side of the membrane	The molecule cannot access the target protein
Whether a delivery receptor is available	Whether the target cells express a delivery receptor capable of mediating endocytosis	Binding occurs, but the complex does not enter the cell
Whether endocytosis occurs	Whether the target protein enters the endosomal system	Surface signal decreases, but total protein may not decrease
Whether it reaches lysosomes	Whether the target protein enters lysosome-marker-positive regions	After internalization, it may be recycled or remain in early endosomes
Whether true degradation occurs	Whether degradation is weakened after lysosomal function is inhibited	Lysosome dependence cannot be demonstrated

The key to the lysosomal pathway is whether the complete delivery chain is established:

1. The target protein is bound.

2. The target protein is internalized.

3. The internalized target protein enters lysosomes.

4. Lysosomal hydrolysis leads to a decrease in the target protein.

5. Reduction of the target protein produces the expected functional change.

6. How to Verify That Target-Protein Reduction Comes from the Expected Degradation Mechanism

Protein reduction is only the starting point; it alone cannot prove that targeted degradation has occurred. Complete validation needs to demonstrate at least four things: target-protein reduction, dependence on the degradation pathway, a reasonable concentration–time relationship, and consistent functional outcomes.

6.1 First Confirm Whether the Target Protein Decreases

Detection method	Suitable scenario	Issues requiring attention
Immunoblotting	Detection of a single target protein	Antibody specificity, loading amount, and stability of the internal control
Quantitative proteomics	Selectivity and off-target degradation profiling	Sufficient replicates and statistical analysis are required
Immunofluorescence	Observation of protein localization and cellular heterogeneity	Reduced fluorescence does not necessarily mean total protein degradation
Flow cytometry	Cell-surface proteins or tagged proteins	Surface masking, internalization, and true degradation need to be distinguished
Reporter system	High-throughput screening	The tag may alter protein localization or stability

If the target-protein signal decreases while cell viability also decreases markedly, cell death, global protein loss, or sample-quality problems need to be excluded.

6.2 Then Demonstrate That the Reduction Depends on the Expected Pathway

Pathway inhibitors themselves may cause cellular stress, protein homeostasis disruption, or toxicity. Therefore, mechanism validation should not rely on a single inhibitor alone. Short treatment duration, controlled dosing, E3 ligand competition, target ligand competition, ubiquitination detection, colocalization analysis, and negative-control degraders should be combined for interpretation.

Technical direction	Mechanistic validation
Proteolysis-targeting chimera	Whether degradation is weakened after proteasome inhibition; whether degradation is weakened after E3 ligand competition; whether target-protein ubiquitination increases
Lysosome-targeting chimera	Whether degradation is weakened after lysosomal function is inhibited; whether the target protein enters lysosomes; whether endocytosis blockade affects degradation
Autophagy-related degradation strategy	Whether autophagic flux changes; whether the target protein, protein aggregate, or damaged organelle enters autophagosomes or lysosomes; whether degradation is weakened after autophagy inhibition

If target-protein reduction is accompanied by a decrease in messenger ribonucleic acid level, transcriptional inhibition needs to be excluded. Targeted degradation should mainly manifest as protein-level clearance rather than simply reduced gene expression.

6.3 Use Concentration and Time Relationships to Assess Degradation Quality

The following parameters are commonly used to describe targeted degradation:

Parameter	Meaning	Experimental significance
Half-degradation concentration	The compound concentration that reduces the target protein by approximately 50% in a specified cell model and treatment duration	Reflects degradation potency; the cell model, treatment time, and detection method should be stated, and it should be interpreted together with the maximum degradation extent
Maximum degradation extent	The maximum degree of protein reduction achievable under the experimental conditions	Reflects degradation depth
Time to onset	The time required for the protein to begin showing a clear decrease	Helps select detection time points
Duration of effect	How long the reduced protein level can be maintained	Reflects persistence of action
Washout recovery	Whether the target protein recovers through new synthesis after compound removal	Helps assess duration of action, compound retention, and protein resynthesis capacity
High-concentration reversal effect	Degradation weakens at high concentrations	Suggests that ternary complex formation may be affected by competition

The half-degradation concentration alone cannot represent molecular quality. A molecule may have a low half-degradation concentration but a small maximum degradation extent, and therefore may still be unsuitable as a functional research tool. Degradation rate, degradation depth, and duration need to be evaluated together.

6.4 Finally Confirm Whether the Functional Outcomes Are Consistent

After the target protein decreases, the following should be further verified:

1. Whether downstream signaling changes as expected.

2. Whether the cellular phenotype is consistent with the biology of the target.

3. Whether homologous proteins are degraded at the same time.

4. Whether the whole proteome shows obvious off-target degradation.

5. Whether cytotoxicity occurs earlier than target-protein reduction.

6. Whether pathway blockade can weaken both protein reduction and functional changes.

Only when protein reduction, pathway dependence, kinetic behavior, and functional outcomes support each other can the targeted degradation mechanism be demonstrated with reasonable confidence.

7. How to Determine Whether the Target Protein Is Worth Further Targeted Degradation Research

Whether a target is suitable for targeted degradation can be divided into three types of conclusions.

Conclusion	Typical features	Next steps
Suitable for prioritized advancement	The target function depends on the presence of the protein; a reliable ligand is available; localization matches the degradation pathway; the detection method is stable	Proceed to degrader design, linker screening, and cellular validation
Conditions need to be improved first	The target value is clear, but the ligand is weak, the attachment site is unclear, E3 selection is uncertain, or the detection system is unstable	First optimize the ligand, establish the cell model, and compare E3 ligases and linkers
Not suitable for prioritized advancement	No binding module is available; the pathway does not match; degradation risk is high; functional readouts are unclear	First consider inhibitors, antibodies, nucleic acid intervention, or genetic models

8. Decision Workflow from Target Value to Mechanism Validation

To determine whether a protein is suitable for targeted degradation, the following sequence can be used:

1. First assess the research question

Determine whether lowering the protein level answers the question better than simply inhibiting its function.

2. Then assess protein location

Determine whether the target protein is located in the cytoplasm, nucleus, cell surface, extracellular space, or an aggregated state.

3. Select the degradation pathway

For intracellular accessible proteins, prioritize evaluation of the ubiquitin–proteasome system; for extracellular proteins and extracellular membrane domains, prioritize evaluation of the lysosomal pathway; for aggregated proteins, damaged organelles, or organelle-related protein complexes, evaluate the autophagy–lysosome direction.

4. Confirm the binding module

Determine whether the target-protein ligand, antibody, peptide, or other binding module is reliable, and whether binding ability is retained after conjugation.

5. Confirm the recruiting module

A proteolysis-targeting chimera requires a suitable E3 ligase ligand; a lysosome-targeting chimera requires a suitable cell-surface delivery receptor ligand.

6. Confirm the spatial configuration

Determine whether linker length, flexibility, hydrophilicity, hydrophobicity, and attachment sites support formation of an effective complex.

7. Confirm mechanistic evidence

Protein reduction, pathway blockade, concentration–time behavior, and functional outcomes must be mutually consistent.

8. Confirm experimental risks

Off-target degradation, cytotoxicity, disruption of protein homeostasis, effects on homologous proteins, and nonspecific interference caused by pathway inhibitors need to be evaluated.

9. Navigation Table of Representative Products Related to Targeted Protein Degradation: Select Tables 1–6 According to Research or Experimental Tasks

Research or experimental objective	Recommended table to consult first	Why this table should be consulted first	Recommended related table	Navigation notes
Determine whether a target protein has the basis for small-molecule degrader design	Table 1	Table 1 focuses on ubiquitin ligase ligands, molecular glue scaffolds, and common target-protein ligands. It can help determine whether the target protein already has an available binding module and whether it has the basis for bifunctional degrader design	Tables 5 and 6	First confirm “which target can be bound and which type of ubiquitin ligase can be recruited,” then use mechanism-validation reagents and positive-control degraders to determine whether the experimental system is suitable for degradation evaluation
Prepare to design a proteolysis-targeting chimera through the ubiquitin–proteasome pathway	Table 1	This type of molecule requires both a target-protein ligand and a ubiquitin ligase ligand. Table 1 helps identify the source of the two terminal ligands	Tables 2 and 3	After the ligands are determined, linkers and coupling reagents need to be considered together to design a molecular series with different lengths, flexibilities, and attachment sites
Compare different recruitment directions, such as cereblon and von Hippel–Lindau protein	Table 1	Table 1 includes cereblon ligands, von Hippel–Lindau protein ligands, and other ubiquitin ligase-related ligands, which can be used for preliminary comparison of different recruitment systems	Tables 5 and 6	After selecting the recruitment direction, pathway-blocking and positive-control experiments should be used to confirm whether target-protein reduction is consistent with a ubiquitin–proteasome-dependent mechanism
Screen linker length, flexibility, and hydrophilicity	Table 2	Table 2 focuses on dicarboxylic acids, anhydrides, polyethers, amino acid-type linkers, and alkyne-containing linkers, which can be used to construct molecular series with different spacer distances and physicochemical properties	Table 3	Linker screening usually requires reactions such as amide coupling, carboxyl activation, and click ligation; Table 3 can be used to select synthetic connection methods
Establish a conjugation route among the target-protein ligand, linker, and recruiting ligand	Table 3	Table 3 includes amide coupling, carbodiimide coupling, active ester, carbonylation, and click chemistry reagents, making it suitable for constructing synthetic routes for bifunctional molecules	Tables 1 and 2	First determine the two terminal ligands according to Table 1, then select the linker according to Table 2, and finally use Table 3 to complete modular conjugation
Construct degrader intermediates containing alkynes, active esters, or copper-free click handles	Table 3	The copper source, reducing agent, and copper-free click reagents in Table 3 can be used for azide–alkyne ligation or active ester coupling, making them suitable for rapidly constructing linker-variation libraries	Table 2	The alkynyl carboxylic acids and other functionalizable linkers in Table 2 can be used together with the reagents in Table 3 to establish a set of structurally related candidate molecules
Determine whether the target protein should be considered for a lysosome-targeted degradation route	Table 4	Table 4 focuses on lysosomal delivery receptor recognition units and glycosylation building blocks, which can be used for research on extracellular proteins, extracellular domains of membrane proteins, and delivery receptors. Actual delivery efficiency must be verified together with receptor expression, multivalent display, internalization, and lysosomal colocalization	Table 5	After designing a lysosome-targeting system, lysosomal acidification, lysosomal protease, and autophagy pathway validation reagents should be used together to confirm whether protein reduction results from lysosomal hydrolysis
Verify whether target-protein reduction depends on the proteasome, lysosome, or autophagy pathway	Table 5	Table 5 focuses on proteasome inhibitors, lysosomal acidification inhibitors, lysosomal protease inhibitors, autophagy pathway inhibitors, and protein synthesis inhibitors, which can be used for mechanistic assessment	Table 6	The positive-control degraders in Table 6 can be used to confirm whether the cell model, detection method, and pathway-blocking experiments are functioning properly
Perform protein half-life, degradation-rate, and washout-recovery experiments	Table 5	The protein synthesis inhibitors and pathway inhibitors in Table 5 can be used to distinguish newly synthesized protein, basal turnover, and induced degradation	Table 6	Positive-control degraders can be used to establish time-course and dose–response curves, followed by comparison with the degradation behavior of the test molecule
Establish a positive-control system for bromodomain protein degradation	Table 6	Table 6 lists known positive controls for bromodomain protein degradation, which can be used to validate the experimental workflow, detection antibodies, and pathway-blocking conditions for proteolysis-targeting chimeras	Tables 1 and 5	After stable positive-control results are obtained, the ligand modules in Table 1 and the pathway-validation reagents in Table 5 can be used to study new targets
Compare the functional differences between “target inhibition” and “target degradation”	Table 1	Table 1 contains multiple types of target-protein ligands and inhibitors, which can be used to establish inhibition controls and observe the differences between simple inhibition and protein clearance in downstream signaling	Tables 5 and 6	Protein reduction, pathway blockade, and positive controls need to be combined to avoid misinterpreting cytotoxicity, transcriptional reduction, or detection variability as targeted degradation

Table 1 | E3 Ligase Ligands, Molecular Glue Scaffolds, and Target-Protein Ligands

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Cereblon ligand / molecular glue scaffold	191732-72-6	L125046	Lenalidomide	Moligand™, ≥99%	Can serve as a ligand scaffold for cereblon-recruiting degrader design and can also be used in studies of molecular glue-induced substrate degradation
Cereblon ligand / molecular glue scaffold	19171-19-8	P125813	Pomalidomide	Moligand™, ≥99%	Commonly used for constructing cereblon-recruiting degraders and suitable for exploring attachment sites between target-protein ligands and linkers
Cereblon ligand / molecular glue scaffold	50-35-1	T126856	Thalidomide	Moligand™, ≥98%	Can serve as a cereblon-binding scaffold for comparing the effects of different immunomodulatory imide structures on degradation activity
von Hippel–Lindau protein ligand	2097381-85-4	V287785	VH 298	≥98% (HPLC)	Can be used for von Hippel–Lindau protein ligand research and competition experiments, helping determine whether degradation depends on this recruitment pathway
von Hippel–Lindau protein ligand	1448189-80-7	S412684	(S,R,S)-AHPC hydrochloride	≥97%	Commonly used for designing von Hippel–Lindau protein-recruiting degraders and can serve as a key ligand module for constructing proteolysis-targeting chimeras
Inhibitor of apoptosis protein ligand / SNIPER-related recruiting module reference	1005342-46-0	L127178	LCL161	Moligand™, ≥99%	Can be used in studies of inhibitor of apoptosis protein-related recruitment strategies; activation of apoptotic pathways, IAP self-degradation, and cytotoxicity should be considered when interpreting results
DCAF15-related molecular glue	165668-41-7	I305112	Indisulam	Moligand™, ≥99%	Can be used in DCAF15-mediated molecular glue degradation studies and is suitable for comparing substrate recruitment modes between molecular glues and bifunctional degraders
MDM2–p53 interaction inhibitor / MDM2 ligand reference	675576-98-4	N129972	Nutlin-3a	≥97%	Can serve as a ligand reference for MDM2-related recruitment studies and as a mechanistic control for the p53–MDM2 pathway; when used in degrader design, its intrinsic interference with p53 stability should be considered
Bromodomain protein target ligand	1268524-70-4	J166817	(+)-JQ1	≥98% (HPLC)	Commonly used as a target-protein ligand module for bromodomain protein degraders and for constructing and evaluating target-protein degradation models
Kinase target ligand	302962-49-8	D125110	Dasatinib (BMS-354825)	Moligand™, ≥99%	Can serve as a kinase target ligand for constructing kinase degraders and comparing the functional differences between degradation and inhibition
Bruton’s tyrosine kinase target ligand	936563-96-1	P127143	Ibrutinib (PCI-32765)	Moligand™, ≥98%	Can serve as a ligand reference for Bruton’s tyrosine kinase-related degrader design and for research on hematologic malignancy-related targets
Poly(ADP-ribose) polymerase target ligand	763113-22-0	O126162	Olaparib (AZD2281, Ku-0059436)	Moligand™, ≥98%	Can serve as a target ligand for poly(ADP-ribose) polymerase degrader design and for studies related to DNA damage repair
Androgen receptor target ligand	915087-33-1	E127109	Enzalutamide	Moligand™, ≥98%	Can serve as a ligand reference for androgen receptor degrader design and for studies on receptor degradation and signaling pathway regulation
Anti-apoptotic protein target ligand	1257044-40-8	A1509661	ABT-199 (GDC-0199)	Moligand™, ≥95%	Can serve as a target ligand reference for anti-apoptotic protein-related degrader design and for comparing protein inhibition with protein clearance effects

Table 2 | Linkers and Functionalizable Building Blocks

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Dicarboxylic acid linker	124-04-9	A108267	Adipic acid	Pharmaceutical grade, PharmPure™, ≥99.6%	Can be used to introduce aliphatic dicarboxylic acid spacer structures and is suitable for constructing amide- or ester-linked degrader intermediates
Polyether linker	112-27-6	T755680	Triethylene glycol	UltraBio™, anhydrous grade, ≥99% (GC)	Can be used to introduce hydrophilic polyether spacer units and adjust the solubility and spatial distance of degrader molecules
Amino acid-type linker	60-32-2	A755726	6-Aminocaproic acid (EACA)	UltraBio™, ≥99%	Contains both amino and carboxyl groups and can serve as an aliphatic spacer unit for the synthesis of amide-linked degraders
Anhydride linker	108-30-5	S104823	Succinic anhydride	≥99%	Can be used to introduce short-chain carboxylic acid spacer structures and is commonly used for carboxylation modification of amino- or hydroxyl-containing molecules
Polyether linker	112-60-7	T111130	Tetraethylene glycol	≥99%	Can be used to construct polyether spacers and adjust the flexibility, hydrophilicity, and spatial length of bifunctional molecules
Protected amino acid-type linker	6404-29-1	B117708	Boc-6-Ahx-OH	≥99%	Suitable for stepwise coupling synthesis and can protect the amino terminus while retaining the carboxyl reactive site
Anhydride linker	108-55-4	G111073	Glutaric anhydride	≥98%	Can be used to introduce a glutaryl spacer structure and is suitable for constructing ligand intermediates bearing terminal carboxyl groups
Protected amino acid-type linker	88574-06-5	F117709	Fmoc-6-aminohexanoic acid	≥98%	Suitable for stepwise coupling in solid-phase or solution-phase synthesis, enabling introduction of an aminohexanoic acid spacer while controlling the reaction sequence
Alkyl halide linker	629-03-8	D106541	1,6-Dibromohexane	≥97%	Can be used to construct linkers through nucleophilic substitution and is suitable for introducing a six-carbon aliphatic spacer
Alkynyl carboxylic acid linker	53293-00-8	H111132	5-Hexynoic acid	≥95%	Contains both a carboxyl group and a terminal alkyne, allowing azide–alkyne click ligation after amide coupling

Table 3 | Coupling, Amidation, and Click Chemistry Reagents

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Click chemistry reducing agent	134-03-2	S105026	Sodium ascorbate	For cell culture, ≥99%	Used in the reducing system for copper-catalyzed azide–alkyne cycloaddition and can help generate active copper species
Click chemistry copper source	7758-99-8	C112411	Copper sulfate pentahydrate	For cell culture, ≥98%	Can serve as a copper source for copper-catalyzed click reactions and is suitable for constructing azide–alkyne-linked degrader intermediates
Organic base	7087-68-5	D109322	N,N-Diisopropylethylamine	Distilled grade, ≥99.5%	Commonly used for acid scavenging and basicity adjustment in amide coupling, active ester reactions, and ligand conjugation steps
Carbodiimide coupling reagent	538-75-0	D106074	N,N′-Dicyclohexylcarbodiimide	≥99%	Used for condensation reactions between carboxylic acids and amines or alcohols, enabling construction of amide- or ester-linked degrader intermediates
Carbonylation / coupling reagent	530-62-1	C109315	N,N′-Carbonyldiimidazole (CDI)	≥99%	Can be used to activate hydroxyl, amino, or carboxyl groups and is suitable for constructing carbonate, carbamate, and amide linkages
Amide coupling reagent	148893-10-1	H109327	HATU	≥99%	Used for efficient amide bond formation and suitable for coupling target-protein ligands, linkers, and recruiting ligands
Amide coupling reagent	94790-37-1	H106174	HBTU	≥99%	Used for amide coupling between carboxylic acids and amines, supporting linker-length screening and bifunctional molecule synthesis
Carbodiimide coupling reagent	25952-53-8	E106172	N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride	≥98%	A commonly used carboxyl-activating reagent in aqueous or mixed solvents; can be used for coupling carboxylic acid ligands with amine-containing modules
Active ester reagent	6066-82-6	H109330	N-Hydroxysuccinimide (NHS)	≥98%	Can be used with carbodiimides to generate active esters, improving the controllability of coupling between carboxylic acids and amine modules
Copper-free click chemistry reagent	1353016-71-3	D595518	DBCO-NHS ester	≥97%	Can be used for active ester coupling with amine-containing molecules and for introducing a cyclooctyne group for copper-free click ligation

Table 4 | Lysosomal Delivery Receptor Recognition Units and Glycosylation Building Blocks

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Mannose-6-phosphate receptor-related ligand	33068-18-7	D350853	D-Mannose-6-phosphate, Disodium Salt hydrate	≥98%	Can be used in research on mannose-6-phosphate receptor-related delivery and is suitable as a design reference for lysosome-targeted degradation pathways
Galactosamine delivery ligand unit	1811-31-0	A113374	N-Acetyl-D-galactosamine	≥98%	Can serve as an asialoglycoprotein receptor recognition-related glycan unit for liver-cell delivery module design; practical application should be verified together with multivalent GalNAc structures and receptor-mediated internalization
Lysosomal delivery ligand	1953146-81-0	T773887	Tri-GalNAc-COOH	≥95%	Can be used to construct delivery molecules mediated by the asialoglycoprotein receptor and is suitable for lysosome-targeting chimera design studies

Table 5 | Degradation Pathway and Mechanism-Validation Reagents

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Lysosomal protease inhibitor	103476-89-7	L274378	Leupeptin	Ultrapure grade, EnzymoPure™	Can be used to inhibit part of lysosomal protease activity and help determine whether target-protein reduction involves lysosomal hydrolysis
Protein synthesis inhibitor	66-81-9	C729197	Cycloheximide	Moligand™, ≥98%	Inhibits protein synthesis in eukaryotic cells and can be used in protein half-life tracking and washout-recovery experiments to help distinguish basal turnover, induced degradation, and protein resynthesis effects
Proteasome inhibitor	133407-82-6	M126521	MG-132	Moligand™, ≥98%	Can be used to verify whether target-protein reduction depends on the proteasome and is a commonly used control in mechanism studies of proteolysis-targeting chimeras
Cullin-RING ligase pathway validation reagent	905579-51-3	M127498	MLN4924	Moligand™, ≥98%	Inhibits NEDD8-activating enzyme and disrupts the neddylation-dependent activity of cullin-RING E3 ligases; can be used to evaluate whether degradation is related to the cullin-RING ligase system
Proteasome inhibitor	179324-69-7	B125789	Bortezomib (PS-341)	Moligand™, ≥98%	Can be used in proteasome-dependent degradation blockade experiments to help confirm whether target-protein reduction depends on the ubiquitin–proteasome system; dosage and treatment duration should be controlled because of cytotoxicity concerns
Lysosomal acidification inhibitor	50-63-5	C129284	Chloroquine Phosphate	≥99%	Can be used to interfere with lysosomal function and autophagic degradation, making it suitable for validating lysosomal pathways and autophagy pathways; its effects on cellular stress and lysosomal homeostasis should be considered
Autophagy pathway inhibitor	5142-23-4	M129496	3-Methyladenine	≥98%	Can be used to interfere with the initiation stage of autophagy and help determine whether degradation of protein aggregates or autophagy-related cargo involves autophagy; results should be interpreted together with LC3, p62, and autophagic flux experiments
Proteasome inhibitor	134381-21-8	E275112	Epoxomicin	≥97%	Can serve as a proteasome inhibition control for verifying target-protein clearance mediated by the ubiquitin–proteasome system
Lysosomal acidification inhibitor	88899-55-2	B101389	Bafilomycin A1	≥95%	Can be used to inhibit the vacuolar-type proton pump, interfere with lysosomal acidification and autophagic flux, and help determine whether target-protein reduction depends on lysosomal function; dosage and treatment duration should be controlled

Table 6 | Representative Positive-Control Degraders

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
von Hippel–Lindau protein-recruiting positive-control degrader	1797406-69-9	M275142	Mz1	Moligand™, ≥98%	Can serve as a positive control for bromodomain protein degradation and is used to validate proteolysis-targeting chimera experimental systems and detection methods
Cereblon-recruiting positive-control degrader	1799711-21-9	B305226	dBET1	≥99%	Can be used to establish bromodomain protein degradation models and is suitable for studies of proteasome-dependent degradation and downstream phenotypes
Cereblon-recruiting positive-control degrader	1818885-28-7	A413965	ARV-825	≥97%	Can be used in bromodomain protein degradation studies and is suitable as a positive control for targeted degradation activity, time-course curves, and pathway-blocking experiments

Note: The above products are representative Aladdin products. More product specifications can be searched on the Aladdin website by “product name/CAS/catalog number.”

References

[1] Békés M, Langley D R, Crews C M. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery, 2022, 21: 181–200.

[2] Sakamoto K M, Kim K B, Kumagai A, Mercurio F, Crews C M, Deshaies R J. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98: 8554–8559.

[3] Bondeson D P, Mares A, Smith I E D, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature Chemical Biology, 2015, 11: 611–617.

[4] Gadd M S, Testa A, Lucas X, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nature Chemical Biology, 2017, 13: 514–521.

[5] Troup R I, Fallan C, Baud M G J. Current strategies for the design of PROTAC linkers: a critical review. Exploration of Targeted Anti-tumor Therapy, 2020, 1: 273–312.

[6] Banik S M, Pedram K, Wisnovsky S, et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature, 2020, 584: 291–297.

[7] Riching K M, Caine E A, Urh M, Daniels D L. The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation. Chemical Society Reviews, 2022, 51: 6210–6221.

[8] Ahn G, Banik S M, Miller C L, et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nature Chemical Biology, 2021, 17: 937–946.

[9] Takahashi D, Moriyama J, Nakamura T, et al. AUTACs: Cargo-Specific Degraders Using Selective Autophagy. Molecular Cell, 2019, 76: 797–810.

[10] Ji C H, Kim H Y, Heo A J, et al. The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system. Nature Communications, 2022, 13: 904.

[11] Thermo Fisher Scientific. Mechanisms of Protein Degradation.

For more related articles, see below:

Targeted protein degradation technology: proprietary drugs are not difficult, drug resistance is no longer

Three Key Components of PROTAC Design: E3 Ligase Ligands, Linkers, and Target Protein Ligands (with an Aladdin Reagent Selection Guide)

Ubiquitin–Proteasome System (UPS)